Nothing Special   »   [go: up one dir, main page]

SG11202108150RA - Methods of treating prostate cancer based on molecular subtypes - Google Patents

Methods of treating prostate cancer based on molecular subtypes

Info

Publication number
SG11202108150RA
SG11202108150RA SG11202108150RA SG11202108150RA SG11202108150RA SG 11202108150R A SG11202108150R A SG 11202108150RA SG 11202108150R A SG11202108150R A SG 11202108150RA SG 11202108150R A SG11202108150R A SG 11202108150RA SG 11202108150R A SG11202108150R A SG 11202108150RA
Authority
SG
Singapore
Prior art keywords
methods
prostate cancer
treating prostate
cancer based
molecular subtypes
Prior art date
Application number
SG11202108150RA
Inventor
Michael Gormley
Shibu Thomas
Aguilar Clemente
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11202108150RA publication Critical patent/SG11202108150RA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202108150RA 2019-01-30 2020-01-30 Methods of treating prostate cancer based on molecular subtypes SG11202108150RA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962799037P 2019-01-30 2019-01-30
US201962799036P 2019-01-30 2019-01-30
US201962801610P 2019-02-05 2019-02-05
US201962801609P 2019-02-05 2019-02-05
US201962824968P 2019-03-27 2019-03-27
US201962825001P 2019-03-27 2019-03-27
US201962938318P 2019-11-20 2019-11-20
PCT/IB2020/050762 WO2020157704A1 (en) 2019-01-30 2020-01-30 Methods of treating prostate cancer based on molecular subtypes

Publications (1)

Publication Number Publication Date
SG11202108150RA true SG11202108150RA (en) 2021-08-30

Family

ID=69570702

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108150RA SG11202108150RA (en) 2019-01-30 2020-01-30 Methods of treating prostate cancer based on molecular subtypes

Country Status (12)

Country Link
US (1) US20210115517A1 (en)
EP (1) EP3918607A1 (en)
JP (1) JP2022524289A (en)
KR (1) KR20210122275A (en)
CN (1) CN113711316A (en)
AU (1) AU2020215177A1 (en)
BR (1) BR112021014657A2 (en)
CA (1) CA3143199A1 (en)
IL (1) IL285056A (en)
MX (1) MX2021009184A (en)
SG (1) SG11202108150RA (en)
WO (1) WO2020157704A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022067197A1 (en) * 2020-09-28 2022-03-31 The Regents Of The University Of California Drug implants containing apalutamide and methods of use thereof
KR102626616B1 (en) * 2021-03-11 2024-01-19 주식회사 디시젠 Prostate cancer subtype classification method and classification apparatus

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
KR102225416B1 (en) 2012-09-11 2021-03-09 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 Formulations of enzalutamide
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
GB201322034D0 (en) * 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
SI3226843T1 (en) 2014-12-05 2021-11-30 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (en) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc ANTI-CANCER COMPOSITIONS
SG11201704264UA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
CN104857157A (en) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 Decoction medicine for treating endometrial hyperplasia and preparation method thereof
US10391173B2 (en) * 2016-04-22 2019-08-27 The Cleveland Clinic Foundation Anti-ar agent and radiation therapy for androgen receptor positive cancer
EP3468584B1 (en) * 2016-06-09 2023-05-31 Wisconsin Alumni Research Foundation Combination therapy consisting of adt and an androgen receptor vaccine

Also Published As

Publication number Publication date
WO2020157704A1 (en) 2020-08-06
MX2021009184A (en) 2021-11-12
JP2022524289A (en) 2022-05-02
BR112021014657A2 (en) 2021-09-21
AU2020215177A1 (en) 2021-08-12
CN113711316A (en) 2021-11-26
IL285056A (en) 2021-09-30
EP3918607A1 (en) 2021-12-08
KR20210122275A (en) 2021-10-08
US20210115517A1 (en) 2021-04-22
CA3143199A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IL275663A (en) Methods of treating cancer
EP3891294A4 (en) Methods for treating castration-resistant and castration- sensitive prostate cancer
IL264443A (en) Methods of treating prostate cancer
IL280158A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077
IL265697B1 (en) Treatment of prostate cancer
EP3606531A4 (en) Methods of treating cancer
IL276748A (en) Methods for prostate cancer detection and treatment
IL287907A (en) Methods for treating cancer
IL277568A (en) Methods of treating minimal residual cancer
IL277981A (en) Methods of treating cancer
SG11202010793UA (en) Methods of treating cancer
IL284850A (en) Methods of treating breast cancer with tucatinib
IL288408A (en) Methods of treating urinary system cancers
EP3852816A4 (en) Methods of treating cancer
IL285056A (en) Methods of treating prostate cancer based on molecular subtypes
IL281281A (en) Combined treatment for prostate cancer
IL279591A (en) Methods of treating cancer using combination therapy
SG11202107017TA (en) Methods of treating cancer
IL289811A (en) Method of treating cancer
SG11202005163PA (en) Methods of treating cancer
IL282738A (en) Methods of treating cancer with farnesyltransferase inhibitors
PT3229830T (en) Methods of treating and prognosing nonhematopoietic malignant tumors
IL290213A (en) Methods of treating multifocal cancer
EP4072561A4 (en) Methods of treating cancer
EP3801547A4 (en) Methods of treating cancer